larotrectinib sold brand name vitrakvi medication treatment inhibitor tropomyosin kinase receptors trka trkb discovered array biopharma licensed loxo oncology larotrectinib initially awarded orphan drug status soft tissue sarcoma breakthrough therapy designation treatment metastatic solid tumors ntrk clinical trial results announced november larotrectinib approved larotrectinib first drug specifically developed approved treat cancer containing certain mutations opposed cancers specific tissues ie approval tissue agnostic several earlier drugs including pembrolizumab eventually approved fda treatment specific mutations independent type cancer drugs initially developed specific cancer us food drug administration fda considers firstinclass phase ii clinical trials evaluating drug efficacy safety treating several types solid tumors larotrectinib approved medical use european union september approved medical use australia august antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikilarotrectinib